# Shionogi Inc. clinical trials: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Shionogi Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Shionogi Inc.: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/shionogi-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 25, 2025 | NCT07247266 | Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic... | Shionogi Inc. | Phase 1 | Completed | Cryopyrin-associated Periodic Syndromes (CAPS) | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07247266) |
| August 30, 2023 | NCT06017609 | Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction | Shionogi Inc. | Phase 2 | Completed | Chronic Heart Failure | 314 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06017609) |
| July 10, 2020 | NCT04465877 | Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes | Shionogi Inc. | Phase 1 | Completed | Diabetes Mellitus, Type 2 | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04465877) |
| February 6, 2019 | NCT03832738 | Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis | Shionogi Inc. | Phase 2 | Completed | Plaque Psoriasis, Psoriasis, Skin Diseases | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03832738) |
| December 28, 2018 | NCT03789643 | Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension | Shionogi Inc. | Phase 2 | Withdrawn | Pulmonary Arterial Hypertension | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03789643) |
| November 30, 2017 | NCT03358290 | Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis | Shionogi Inc. | Phase 2 | Terminated | Plaque Psoriasis, Skin Diseases | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03358290) |
| January 12, 2017 | NCT03018509 | Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects | Shionogi Inc. | Phase 1 | Completed | Plaque Psoriasis, Psoriasis, Skin Diseases | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03018509) |
| September 29, 2016 | NCT02919475 | Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis | Shionogi Inc. | Phase 2 | Completed | Rheumatoid Arthritis | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02919475) |
| June 17, 2016 | NCT02805244 | Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis | Shionogi Inc. | Phase 1 | Completed | Anemia of Chronic Kidney Disease | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02805244) |
| October 20, 2015 | NCT02581124 | Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease | Shionogi Inc. | Phase 1 | Completed | Anemia of Chronic Kidney Disease | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02581124) |
| April 23, 2014 | NCT02120976 | Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252 | Shionogi Inc. | Phase 1 | Terminated | Diabetes Mellitus | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02120976) |
| April 8, 2014 | NCT02106585 | Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects | Shionogi Inc. | Phase 1 | Completed | Diabetes Mellitus | 94 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02106585) |
| November 7, 2013 | NCT01978587 | Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease | Shionogi Inc. | Phase 1 | Completed | Anemia in Chronic Kidney Disease | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01978587) |
| October 29, 2013 | NCT01971164 | Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease | Shionogi Inc. | Phase 1 | Completed | Anemia of Chronic Kidney Disease | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01971164) |
| October 4, 2012 | NCT01699737 | Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus | Shionogi Inc. | Phase 2 | Completed | Type 2 Diabetes Mellitus | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01699737) |
| November 22, 2011 | NCT01475981 | Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects | Shionogi Inc. | Phase 1 | Completed | Healthy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01475981) |
| November 17, 2011 | NCT01473069 | Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects | Shionogi Inc. | Phase 1 | Terminated | Healthy | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01473069) |
| November 17, 2011 | NCT01473056 | Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects | Shionogi Inc. | Phase 1 | Completed | Hepatitis C Virus Infection, Response to Therapy of | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01473056) |
| October 19, 2009 | NCT00997152 | Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients | Shionogi Inc. | Phase 2 | Terminated | Type II Diabetes Mellitus | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00997152) |
| June 29, 2009 | NCT00929539 | Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients | Shionogi Inc. | Phase 2 | Completed | Type II Diabetes Mellitus | 496 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00929539) |
| September 9, 2008 | NCT00749788 | Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels | Shionogi Inc. | Phase 2 | Completed | Dyslipidemia | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00749788) |
| September 9, 2008 | NCT00748852 | Safety Study of JTT-302 in Subjects With Low HDL-C Levels | Shionogi Inc. | Phase 2 | Completed | Dyslipidemia | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00748852) |
| June 3, 2008 | NCT00689442 | Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels | Shionogi Inc. | Phase 2 | Completed | Dyslipidemia | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00689442) |
| June 3, 2008 | NCT00688896 | Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia | Shionogi Inc. | Phase 2 | Completed | Type II Hyperlipidemia | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00688896) |
| June 3, 2008 | NCT00688558 | Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels | Shionogi Inc. | Phase 2 | Completed | Dyslipidemia | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00688558) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 2 | 13 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 20 |
| Terminated | 4 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus | 6 |
| Dyslipidemias | 4 |
| Diabetes Mellitus, Type 2 | 4 |
| Skin Diseases | 3 |
| Psoriasis | 3 |
| Cryopyrin-Associated Periodic Syndromes | 1 |
| Anemia | 1 |
| Renal Insufficiency, Chronic | 1 |
| Hyperlipoproteinemia Type II | 1 |
| Arthritis, Rheumatoid | 1 |
| Kidney Failure, Chronic | 1 |
| Heart Failure | 1 |
| Hepatitis C | 1 |
| Pulmonary Arterial Hypertension | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Medical transportation companies in the United States](https://specstream.ai/data/businesses/medical-transportation-companies/united-states)
- [Financial services firms in the United States](https://specstream.ai/data/businesses/financial-services-firms/united-states)
- [British restaurants in the United States](https://specstream.ai/data/businesses/british-restaurants/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
- [Pediatric oncology practices in the United States](https://specstream.ai/data/businesses/pediatric-oncology-practices/united-states)
- [Hospital equipment suppliers in the United States](https://specstream.ai/data/businesses/hospital-equipment-suppliers/united-states)
